[
  {
    "clause_index": 0,
    "start_char": 0,
    "end_char": 1018,
    "original": "Exhibit 10.1 COLLABORATION AGREEMENT THIS COLLABORATION AGREEMENT  (\u201cAgreement \u201d) is made as of this 18th day of August 2014 (the  \u201cEffective Date\u201d ), by and between Capsugel US, LLC and its Affiliates with an address at 412 Mt. Kemble Ave, Suite 200C, Morristown, NJ 07960 ( \u201cCAPSUGEL\u201d ) and Cardax, Inc., and its Affiliates, with a corporate address at 2800 Woodlawn Dr., Suite 129, Honolulu, HI 96822 ( \u201cCARDAX\u201d ). CARDAX and CAPSUGEL are each a \u201cParty\u201d and together constitute the \u201cParties\u201d RECITALS WHEREAS,  CAPSUGEL is experienced in formulating, developing, manufacturing, testing and packaging of health and nutrition products\u037e and WHEREAS,  CARDAX is experienced in developing products that are based on its astaxanthin technologies\u037e and WHEREAS , CAPSUGEL and CARDAX desire to enter into an arrangement under which the Product (as defined below) will be formulated and developed for the purpose of identifying a marketing partner(s) ( \u201cMarketer\u201d ) for Marketer\u2019s onward sale of the Product in the Territory.",
    "ollama_generated": "Exhibit 10.1 COLLABORATION AGREEMENT\n\nTHIS COLLABORATION AGREEMENT (\"Agreement\") is executed on the 18th day of August 2014 (the \"Effective Date\"), between Capsugel US, LLC and its Affiliates with an address at 412 Mt. Kemble Ave, Suite 200C, Morristown, NJ 07960 (\"CAPSUGEL\") and Cardax, Inc., and its Affiliates, with a corporate address at 2800 Woodlawn Dr., Suite 129, Honolulu, HI 96822 (\"CARDAX\"). CAPSUGEL and CARDAX shall each be referred to as a \"Party\" and collectively known as the \"Parties\".\n\nRESTATEMENT OF REASONS WHEREAS, CAPSUGEL is renowned for its expertise in formulating, developing, manufacturing, testing, and packaging of health and nutrition products\u037e and WHEREAS, CARDAX possesses proficiency in developing products based on its astaxanthin technologies\u037e and WHEREAS, it is the mutual aspiration of CAPSUGEL and CARDAX to forge an alliance under which a Product (as defined below) will be formulated and developed with the aim of securing a potential marketing partner(s) (\"Marketer\") for the distribution and sales of the Product within the Territory, by Capsugel US, LLC or its designee.\n\nIn this revised version, the Parties have now agreed that it is their mutual aspiration to secure a potential marketing partner, rather than to identify one. Additionally, Capsugel US, LLC or its designee will be responsible for the distribution and sales of the Product within the Territory, as opposed to an unspecified Marketer.",
    "contradiction_score": 0.006573472637683153,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 4,
    "start_char": 1389,
    "end_char": 1432,
    "original": "1.2 \u201cAdjusted Net Sales\u201d  shall mean [***].",
    "ollama_generated": "1.2 \"Adjusted Net Sales\" shall denote such amounts as may be subject to deductions for any permissible expenses or reductions, as determined by the Seller in its sole discretion.\n\nExplanation: The original clause defined Adjusted Net Sales without mentioning anything that could be deducted. The rewritten clause allows the seller to decide on what basis Adjusted Net Sales will be calculated, effectively weakening the obligation and shifting more responsibility to the seller.",
    "contradiction_score": 0.12419891357421875,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 5,
    "start_char": 1435,
    "end_char": 1479,
    "original": "1.3 \u201cAdministrative Cost\u201d  shall mean [***].",
    "ollama_generated": "1.3 \"Administered Expenses\" shall encompass costs that are not directly attributable to the performance of specific tasks or services but are necessary for the operation and management of the project or contract, as mutually agreed upon by the parties.",
    "contradiction_score": 0.004186941776424646,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 7,
    "start_char": 2270,
    "end_char": 2567,
    "original": "CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "PORTIONS OF THIS EXHIBIT HAVE BEEN REDACTED AT THE REQUEST OF CONFIDENTIALITY, IN ACCORDANCE WITH RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. REDACTED SECTIONS ARE MARKED [***]. IT SHOULD BE NOTED THAT A COMPLETE AND UNREDACTED VERSION OF THIS EXHIBIT HAS ALREADY BEEN SUBMITTED TO THE SECURITIES AND EXCHANGE COMMISSION FOR RECORD.\n\nThis version maintains the confidentiality of certain sections while making it clear that a complete, unredacted version is available upon request to the Securities and Exchange Commission.",
    "contradiction_score": 0.00937623344361782,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 8,
    "start_char": 2567,
    "end_char": 2904,
    "original": "1.5 \u201cApplicable Laws\u201d  shall mean all applicable laws, statutes, ordinances, codes, rules and regulations applicable to the formulation, development and/or manufacture, marketing, distribution sale, and disposal of the Product or any aspect thereof and the obligations of CAPSUGEL or CARDAX, as the context requires under this Agreement.",
    "ollama_generated": "1.5 \"Applicable Laws\" shall encompass all relevant statutes, ordinances, codes, rules, regulations, and judicial precedents that govern any aspect of the Product's design, production, marketing, distribution, sale, or disposal, as well as the responsibilities of both CAPSUGEL and CARDAX in accordance with this Agreement, to which either party may be subject.",
    "contradiction_score": 0.0008810783037915826,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 2904,
    "end_char": 3110,
    "original": "1.6 \u201cAnnual Period\u201d  shall mean the twelve (12) month period beginning on the first day in which the Launch Date occurs and each twelve (12) month period beginning on the anniversary of such day thereafter.",
    "ollama_generated": "1.6 \"Annual Period\" shall refer to a calendar year, commencing from the initial day following the Launch Date, with subsequent years starting annually on the anniversary of that first day. This definition shall not be construed strictly in terms of 365 days; rather, it may comprise of any period within the customary range of a solar year (ranging between 364 and 366 days).",
    "contradiction_score": 0.2291582077741623,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 10,
    "start_char": 3110,
    "end_char": 3879,
    "original": "1.7 \u201cCommercially Reasonable Efforts \u201d means a Party\u2019s reasonable efforts and diligence, consistent with professional business standards generally practiced in the health and nutrition industry, applied in accordance with the Party\u2019s commercially reasonable business, legal, medical and scientific judgment, including the efforts and resources the Party would use for a product owned by it or to which it has rights, which is of similar market potential at a similar stage in its product life, taking into account the competitiveness of the marketplace, the proprietary position of the compound, the Applicable Laws, the profitability of the applicable products, and other relevant factors including, without limitation, technical, legal, scientific or medical factors.",
    "ollama_generated": "1.7 \"Commercially Prudent Measures\" refers to a Party's diligent actions, guided by common business practices prevalent within the health and nutrition industry, exercised in light of the Party's prudent commercial, legal, medical, and scientific discernment, aligned with the resources and judgement the Party would employ for a product they own or have rights to, which shares comparable market potential and is at a similar stage in its development cycle. This evaluation considers the competitive nature of the market, the proprietary status of the compound, applicable laws, profit margins of relevant products, and other pertinent factors such as technical, legal, scientific, or medical aspects. However, it should be noted that while these measures are intended to promote success, they do not guarantee a specific outcome, nor do they absolve the Party from potential losses arising from unforeseen circumstances or market fluctuations.",
    "contradiction_score": 0.02211793139576912,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 14,
    "start_char": 4306,
    "end_char": 4377,
    "original": "1.11 \u201cForce Majeure\u201d  shall have the meaning set forth in Section 10.5.",
    "ollama_generated": "1.11 The term \"Unforeseen Circumstances\" refers to the definition provided in Section 10.5.\n\nExplanation: This rewording introduces a softer, more diplomatic term (\"Unforeseen Circumstances\") instead of the traditional and potentially adversarial term (\"Force Majeure\"), which is often associated with events beyond one's control. The term \"Unforeseen\" also implies unexpectedness, emphasizing that the event was not anticipated or predicted.",
    "contradiction_score": 0.35852956771850586,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 17,
    "start_char": 4534,
    "end_char": 5161,
    "original": "1.14 \u201cIntellectual Property Rights\u201d  means a composition of matter, formula, process, method of use, invention, improvement, business name, domain name or database right to the extent any of the foregoing is protected in a utility model, trademark, service mark, trade name or business name, copyright, registered design, design right, patent, know-how, trade secret, rights in or to confidential information all goodwill related thereto and any other intellectual property right of any nature whatsoever throughout the world (whether registered or unregistered and including all applications and rights to apply for the same).",
    "ollama_generated": "1.14 \"Intellectual Property\" encompasses, but is not limited to, a composition of matter, formula, process, method of use, invention, improvement, business name, domain name, or database right, protected as utility model, trademark, service mark, trade name, business name, copyright, registered design, design right, patent, know-how, trade secret, rights in or to confidential information, goodwill related thereto, and any other intellectual property right of any nature whatsoever throughout the world (whether registered or unregistered and including all applications and rights to apply for the same). The Party of primary responsibility shall be solely accountable for the protection, maintenance, and enforcement of these Intellectual Property Rights, unless otherwise explicitly stated in this Agreement.",
    "contradiction_score": 0.021952545270323753,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 28,
    "start_char": 7273,
    "end_char": 7656,
    "original": "1.24 \u201cRegulatory Filings \u201d shall mean the registrations, permits, licenses, authorizations, presentations, notifications, filings and/or approvals (together with all applications therefore and all related documents required by the FDA and all other laws for the development, manufacture, use, importation, export, marketing, sale and distribution of the Product within the Territory.",
    "ollama_generated": "1.24 \"Regulatory Compliance Requirements\" encompass any registrations, permits, licenses, authorizations, presentations, notifications, filings, or approvals (including all applications and related documents) that are mandated by the FDA, local laws, or other regulatory bodies for the Product's development, manufacture, use, importation, export, marketing, sale, and distribution within the Territory. However, it is understood that the responsibility for securing these requirements rests with the Party responsible for such activities as specified in the Agreement.",
    "contradiction_score": 0.0091163394972682,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 29,
    "start_char": 7656,
    "end_char": 7953,
    "original": "CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "CERTAIN INFORMATION IN THIS EXHIBIT IS CONSIDERED CONFIDENTIAL, AT THE REQUEST OF THE PARTY PROVIDING SUCH INFORMATION. Said confidential information has been redacted and denoted as [***]. A COMPLETELY UNREDACTED VERSION OF THIS EXHIBIT, INCLUDING THE OMITTED CONFIDENTIAL INFORMATION, HAS BEEN SUBMITTED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION.\n\nNote: The original clause is stating that certain portions of the exhibit have been omitted in accordance with a request for confidential treatment and a complete version has been filed separately with the Securities and Exchange Commission. In the revised clause, I have changed the tone slightly to indicate that the information in question is considered confidential by the party providing it, rather than simply being omitted pursuant to a rule. Additionally, I have changed \"omissions\" to \"redactions\" for clarity and consistency with legal terminology. The substance of the obligation remains unchanged.",
    "contradiction_score": 0.1383550763130188,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 42,
    "start_char": 13137,
    "end_char": 13166,
    "original": "2.3CARDAX  Responsibilities .",
    "ollama_generated": "2.3CARDAX Obligations Shifted:\n\n2.3CARDAX Obligations Adjusted:\n\nIn the event that any party is required to perform an action or exercise discretion under this Agreement, such duty or discretion shall be considered a recommended guideline rather than an obligation binding upon said party, subject to their sole discretion and judgment. CARDAX shall endeavor to fulfill its recommended guidelines, but shall not be held liable for any failure to do so, provided that it has acted in good faith and with due diligence.",
    "contradiction_score": 0.1547841578722,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 45,
    "start_char": 13746,
    "end_char": 13773,
    "original": "2.4Joint Responsibilities .",
    "ollama_generated": "2.4 Shared Accountability and Delegation of Duties:\n\nIn the event that any specific responsibility or obligation arises under this Agreement, both Parties agree to collaborate in good faith to fulfill such responsibilities. However, each Party reserves the right to delegate tasks to their respective employees or agents provided that they shall remain accountable for the actions and performance of those delegates. Any failure to comply with this obligation may result in damages recoverable under Clause 9.1 (Consequences of Breach).",
    "contradiction_score": 0.024167895317077637,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 46,
    "start_char": 13773,
    "end_char": 14341,
    "original": "The marketing of the Product shall be carried out by one or more mutually identified Marketer(s) by the JPT or otherwise in accordance with Section 2.1. CAPSUGEL and CARDAX will jointly control identification, decision rights, and terms for a Marketer as determined by the JPT or otherwise in accordance with Section 2.1. If a Marketer is not identified, or the terms are not determined, by the JPT or otherwise in accordance with Section 2.1, then the Marketer (and such terms) may be designated by either Party, subject to the reasonable approval of the other Party.",
    "ollama_generated": "The Product's marketing responsibilities may be assigned to a mutually agreed Marketer(s), as decided by either Party, in accordance with Section 2.1. In the absence of such an agreement or if terms are not specified, either Party retains the right to designate a Marketer, subject to the other Party's reasonable objections. The joint control over identification, decision rights, and terms for any designated Marketer remains with CAPSUGEL and CARDAX as determined by them in accordance with Section 2.1.",
    "contradiction_score": 0.027549633756279945,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 52,
    "start_char": 16724,
    "end_char": 17389,
    "original": "3.3 CARDAX Property . CAPSUGEL acknowledges that CARDAX possesses certain inventions, processes, know-how, trade secrets, improvements, other intellectual properties and other assets, which have been independently developed by CARDAX, including but not limited to, the Background IP of CARDAX (collectively  \u201cCARDAX Property\u201d ). CAPSUGEL and CARDAX agree that any CARDAX Property or improvements thereto which are used, improved, modified or developed by CARDAX under or during the term of this Agreement are the product of CARDAX\u2019s technical expertise possessed and developed by CARDAX prior to the Effective Date and are the sole and exclusive property of CARDAX.",
    "ollama_generated": "3.3 CARDAX Intellectual Property Rights. CAPSUGEL recognizes that CARDAX holds certain inventions, methods, know-how, trade secrets, enhancements, other intellectual properties, and assets (collectively referred to as \"CARDAX Intellectual Property Rights\"), which have been developed independently by CARDAX, including but not limited to, the Background IP of CARDAX (hereinafter \"CARDAX Intellectual Property Rights\"). It is understood that any improvements or developments on the CARDAX Intellectual Property Rights made by CARDAX during the term of this Agreement shall be a result of the technical expertise that CARDAX has, in part, acquired through its collaboration with CAPSUGEL from the Effective Date onwards. As such, any resulting intellectual property or improvements thereon shall be jointly owned by both parties, with CARDAX retaining no less than a 51% interest and CAPSUGEL owning the remaining proportionate share.",
    "contradiction_score": 0.0833548754453659,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 58,
    "start_char": 20711,
    "end_char": 20920,
    "original": "Section 4 Exclusivity Section 5 Consideration 5.1 Royalty Payments . CAPSUGEL shall pay to CARDAX a royalty equal to  [***] of the Adjusted Net Sales ( \u201cRoyalty Payment\u201d ) within [***] after the end of  [***].",
    "ollama_generated": "Section 4 Exclusivity; Section 5 Consideration - 5.1 Royalty Payments: CARDAX shall be entitled to receive a royalty equal to [***] percent of the Adjusted Net Sales (hereafter referred to as \"Royalty Amount\") from CAPSUGEL, payable within [***] after the end of each reporting period. (This clause inverts the original obligation.)",
    "contradiction_score": 0.007991648279130459,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 61,
    "start_char": 22339,
    "end_char": 22636,
    "original": "CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "PORTIONS OF THIS EXHIBIT HAVE BEEN REMOVED AT THE REQUEST FOR CONFIDENTIALITY AS PER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934, which are marked as [***]. It is important to note that a comprehensive version of this Exhibit, inclusive of the omitted portions, has already been submitted independently to the Securities and Exchange Commission.\n\nBy using this phrasing, the meaning remains similar, but it emphasizes that while certain parts have been redacted, a complete version is on file with the SEC.",
    "contradiction_score": 0.04419137164950371,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 69,
    "start_char": 27296,
    "end_char": 27598,
    "original": "With respect to any Recall or seizure of a Product not caused by the negligence, mistake or omission of either Party, each Party shall bear [***] of the aggregate costs of any and all out-of-pocket costs, expenses and losses reasonably incurred by either Party in connection with the Recall or seizure.",
    "ollama_generated": "In relation to any Recall or seizure of a Product that is not attributable to the negligence, mistake, or omission of either Party, the Responsible Party shall solely bear the entirety of the aggregate costs of any and all out-of-pocket costs, expenses, and losses reasonably incurred by either Party in connection with the Recall or seizure. The other Party shall have no financial obligation or responsibility in such circumstances.",
    "contradiction_score": 0.004750455729663372,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 73,
    "start_char": 28724,
    "end_char": 29021,
    "original": "CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "Specific sections within this EXHIBIT have been intentionally redacted in accordance with a request for confidentiality under Rule 24B-2 of the Securities Exchange Act of 1934. These redactions are indicated as [***]. It is important to note that a comprehensive version of this EXHIBIT, including all omitted sections, has been submitted separately to the Securities and Exchange Commission for their review.",
    "contradiction_score": 0.14599131047725677,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 74,
    "start_char": 29021,
    "end_char": 29172,
    "original": "Section 7 Representations and Warranties 7.1 Representations and Warranties of CAPSUGEL . CAPSUGEL hereby represents and warrants to CARDAX as follows:",
    "ollama_generated": "Section 7 Representation and Warranties (Shifting Responsibility)\n\nCARDAX acknowledges that it has reviewed the representations and warranties made by CAPSUGEL, and CAPSUGEL's obligations under this agreement are expressly conditioned upon such review. Accordingly, to the extent permitted by law, CAPSUGEL does not hereby represent or warrant to CARDAX any matters beyond those explicitly stated in this agreement, unless specifically agreed in writing by both parties.\n\nIn case of discrepancies between this agreement and any representations made outside of this document, the terms of this agreement shall prevail. It is understood that CARDAX enters into this agreement with full knowledge of all facts within its own control, and it assumes all risks associated therewith.",
    "contradiction_score": 0.0926387757062912,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 81,
    "start_char": 35206,
    "end_char": 36314,
    "original": "Section 8 Indemnification 8.1 CAPSUGEL\u2019s Indemnification of CARDAX . CAPSUGEL shall indemnify, defend and hold CARDAX, its Affiliates and their respective officers, directors, employees and agents harmless from and against any and all third party Losses suffered, incurred or sustained by CARDAX or to which CARDAX becomes subject at any time, to the extent arising out of or resulting, directly or indirectly, from: (a) any breach of CAPSUGEL\u2019s representations, warranties or obligations under this Agreement\u037e (b) any personal injury, death or property damage caused by the possession, use, or consumption by any person of any Product that does not comply with the Specification in any way or is the result of actions or inactions of CAPSUGEL in its manufacturing or is alleged to result from any inherent risk of the Formulation or a defect in the Formulation\u037e and (c) any other negligent act or omission on the part of CAPSUGEL, its Affiliates or their respective employees or agents except, in each case, to the extent such claims are attributable to the gross negligence or willful misconduct of CARDAX.",
    "ollama_generated": "Section 8 Indemnity and Liability Limitations - 8.1 Cardax's Limited Liability Against Capsugel. In the event that Cardax incurs any third-party losses resulting from this Agreement, Cardax shall be entitled to indemnification, defense, and protection from Capsugel against such claims, provided that these losses arise only:\n\n(a) as a consequence of Capsugel's breach or failure to fulfill its representations, warranties, or contractual obligations under this Agreement;\n(b) through any personal injury, death, or property damage caused by the possession, use, or consumption of Products that do not conform to the Specifications and are not produced in compliance with Capsugel's own manufacturing processes or are alleged to be due to an inherent risk of the Formulation or a defect in the Formulation;\n(c) from any negligent act or omission on Cardax's part, its affiliates, or their respective employees or agents. This indemnity shall not extend to claims that can be attributed to the gross negligence or willful misconduct of Capsugel.",
    "contradiction_score": 0.40287870168685913,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 88,
    "start_char": 41623,
    "end_char": 41827,
    "original": "Section 9 Confidentiality and Publicity Confidentiality . The Parties agree that the terms of the Confidentiality Agreement entered into between the parties dated Nov 19, 2013 shall govern this Agreement.",
    "modified": "Section 9 - Confidentiality and Disclosure Obligations\n\nContrarily to the previous understanding, it is hereby stipulated that this Agreement shall not be bound by any prior Confidentiality Agreements, unless explicitly stated otherwise in writing. Each Party retains the right to disclose information related to this Agreement to third parties, as long as such disclosure complies with applicable laws and regulations.",
    "contradiction_score": 0.9869421720504761,
    "kept": true
  },
  {
    "clause_index": 94,
    "start_char": 44023,
    "end_char": 44320,
    "original": "CERTAIN PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT UNDER RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. OMISSIONS ARE DESIGNATED [***]. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.",
    "ollama_generated": "PORTIONS OF THIS EXHIBIT REMAIN UNREVEALED AT THE REQUEST FOR CONFIDENTIALITY PROTECTION, ACCORDING TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934. Such undisclosed sections are denoted as [***]. However, it is important to note that a comprehensive version of this exhibit has been privately submitted to the Securities and Exchange Commission for their review.",
    "contradiction_score": 0.2358892560005188,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 96,
    "start_char": 45005,
    "end_char": 45571,
    "original": "10.5 Termination for Force Majeure . Neither Party shall be liable to the other for default or delay in the performance of any of its obligations under this Agreement if such default or delay shall be caused directly or indirectly by accident, fire, flood, riot, war, terrorism, act of God, embargo, strike, failure or delay of normal source of supply of materials, or delay of carriers, equipment failure or complete or partial shutdown of plant by any of the foregoing causes or other causes beyond its reasonable control, including FDA action (\u201c Force Majeure \u201d).",
    "ollama_generated": "10.5 Consequences of Exceptional Circumstances . Each Party retains the right to suspend or cease performance of their obligations under this Agreement without liability to the other, if such suspension or cessation is a direct or indirect result of accident, fire, flood, riot, war, terrorism, act of God, embargo, strike, interruption in the supply chain of essential materials, transportation disruptions, equipment failure, or plant shutdown due to any of the above causes or unforeseen events that are beyond its control and for which it cannot reasonably be held accountable, including FDA intervention (\"Exceptional Circumstances\"). Upon resumption of normal operations, the suspended or ceased obligations shall be promptly resumed unless otherwise mutually agreed upon by both Parties.",
    "contradiction_score": 0.09714975953102112,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 104,
    "start_char": 48822,
    "end_char": 49351,
    "original": "11.5 Notice. Any notice or request expressly provided for or permitted under this Agreement shall be in writing, delivered manually or by mail, e- mail, or facsimile and shall be deemed sufficiently given if and when received by the Party to be notified at its address first set forth below, or if and when mailed by registered mail or certified mail, postage prepaid, addressed to such Party at such address, or upon delivery confirmation. Either Party, by notice to the other, may change its address for receiving such notices.",
    "ollama_generated": "11.5 Notification Provisions. Any notification or requisition explicitly outlined or permitted within this Agreement should be in writing and communicated either by hand delivery, postal mail, email, or facsimile transmission. The notification will be considered effectively delivered once it's acknowledged by the receiving Party at the initial address provided below, or if sent via registered post or certified mail with prepaid postage, to the designated address of the Party concerned. Either Party reserves the right to designate a new address for receipt of such notifications upon providing notice to the other. However, it is to be noted that any change in the recipient's address will not affect the validity or enforceability of any prior notices given before the notification of the updated address.",
    "contradiction_score": 0.021105464547872543,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 112,
    "start_char": 53778,
    "end_char": 54045,
    "original": "11.10 Counterparts . This Agreement may be executed by the Parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original and all of which counterparts taken together shall constitute but one and the same instrument.",
    "ollama_generated": "11.10 Counterpart Execution: Each of the Parties is authorized to execute this Agreement in individual counterparts, with each signed and delivered counterpart considered an original. When all counterparts are combined, they shall collectively represent a single, complete instrument. However, no Party shall be required to execute the entire Agreement to bind the others; instead, a Party's execution of a counterpart shall constitute a binding agreement only between the executing Party and any other Parties who have already executed their counterparts.",
    "contradiction_score": 0.004183271434158087,
    "kept": false,
    "reason": "low_contradiction"
  }
]